Fingerprick Autologous Blood (FAB) in Severe Dry Eye Disease (DED) (FAB)
|ClinicalTrials.gov Identifier: NCT03395431|
Recruitment Status : Unknown
Verified November 2017 by Bedford Hospital NHS Trust.
Recruitment status was: Not yet recruiting
First Posted : January 10, 2018
Last Update Posted : January 10, 2018
|Condition or disease||Intervention/treatment||Phase|
|Dry Eye Syndromes||Other: Fingerprick autologuos blood (FAB)||Not Applicable|
Autologous serum (AS) eye drops have been found in uncontrolled trials to be beneficial in DED patient by improving the ocular surface and reducing symptoms. Obtaining autologous serum requires frequent drawing of blood from the patient— a feature that excludes patients with anaemia or heart failure from using AS. Furthermore it also appears that 100% autologous serum is more beneficial than 50% serum and requires larger volumes of blood and/or more frequent venesection. Patients using AS also require access to a fridge as the product needs to be stored at low temperatures; a factor that is likely to be inconvenient for patients. In addition, AS is obtained by processing clotted blood which is often too expensive for the health service to consistently purchase, given the initial cost of £1653.56 and subsequent three-monthly cost of £1131.27 per patient.
The relatively high cost represents the biggest hurdle in the use of AS and is often the reason for delay or inaccessibility in starting treatment for DED using AS. However, we propose that finger prick autologous blood may be a simpler, cost-effective and possibly more acceptable method for treating dry eye disease. For this reason, this study proposes to test the use of finger prick autologous blood (FAB) technique in which whole blood is applied to the eye from a cleaned finger.
The proposing team have completed an exploratory study on the use of finger-prick autologous blood (FAB) for persistent epithelial defects and severe dry eye disease and preliminary results indicate improvement with no adverse events reported. The exploratory study included 16 patients with a diagnosis of severe to moderate dry eye syndrome and used the FAB method for treatment. The findings of the study demonstrated mean improvements in visual acuity, Oxford corneal staining grade, tear breakup time, Schirmer's test and dry eye disease questionnaire score. The response rate from participants was good with only a single patient who met the inclusion criteria not wishing to participate in the trial on the advice of their general practitioner. Both the amount of staining (indicating inflammation and ocular surface damage) and their DED questionnaire scores (indicating severity of their symptoms and impact on quality of life) showed mean improvement which reached statistical significance.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||A single blind parallel group randomized control trial|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||The outcome assessor will be blinded to group assignment|
|Official Title:||The Feasibility of Fingerprick Autologous Blood (FAB) As a Novel Treatment for Severe Dry Eye Disease (DED)|
|Estimated Study Start Date :||February 2018|
|Estimated Primary Completion Date :||April 2019|
|Estimated Study Completion Date :||July 2019|
Active Comparator: FAB group
Arm A - Finger prick autologous blood (FAB) plus conventional treatment The patients will use FAB alongside conventional therapy as recommended by their treating ophthalmologist. A fingertip of the hand will be wiped with an alcohol steret and self-pricked using a standard diabetic lancet. The drop of blood is produced as normal and applied to the lower fornix of the affected eye(s) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards
Other: Fingerprick autologuos blood (FAB)
Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
Other Name: FAB
No Intervention: Control group
Arm B - Conventional treatment only The patients will use conventional therapy (artificial tears, cyclosporin drops and punctal plugs/cautery) as recommended by their treating ophthalmologist
- Number of patients recruited into the study within the specified time frame [ Time Frame: 12 months ]This will involve specifically assessing the number of eligible patient in study population consented and randomized.
- Number of patients who adhere to trial protocol [ Time Frame: 12months ]Measured by self-reported adherence to trial protocol
- Reduction in corneal inflammation as indicated by staining on front of the eye [ Time Frame: 3 months ]Assessed using the Oxford Corneal Staining Guide graded on a scale from 0 to 5 in order of increasing severity
- Patient pain and symptoms scores [ Time Frame: 3 months ]This will be assessed by Ocular Surface Disease Index (OSDI) score assessed on a scale of 0 to 100 with higher score representing severity
- Improvement in objective signs of dry eye disease as indicated by visual acuity [ Time Frame: 3 months ]This will be assessed using the Snellen chart
- Willingness for patients to be randomised and acceptability of the intervention [ Time Frame: 3 months ]This will be assessed by structured qualitative interviews
- Impact on patients' quality of life [ Time Frame: 3 months ]This will be assessed by EQ-5D-5L score with higher scores indicating improvement in quality of life
- Cost to the NHS and patient [ Time Frame: 3 months ]This will be assessed by use of additional NHS services and privately purchased over the counter treatments related to dry eyes disease
- Intraocular pressure (IOT) [ Time Frame: 3 months ]Intraocular pressure will be measured to assessed safety of the intervention
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03395431
|Contact: Anant Sharma, MDfirstname.lastname@example.org|
|Contact: Shafi Balal, MBBSemail@example.com|